-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Neuraminidase -X- _ O
inhibitors -X- _ O
are -X- _ O
thought -X- _ O
to -X- _ O
be -X- _ O
efficacious -X- _ O
in -X- _ O
reducing -X- _ O
the -X- _ O
time -X- _ O
to -X- _ O
alleviation -X- _ O
of -X- _ O
symptoms -X- _ O
in -X- _ O
outpatients -X- _ O
with -X- _ O
seasonal -X- _ O
influenza. -X- _ O
The -X- _ O
objective -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
compare -X- _ O
the -X- _ O
short-term -X- _ O
virological -X- _ O
efficacy -X- _ O
of -X- _ O
oseltamivir-zanamivir -X- _ B-Intervention
combination -X- _ I-Intervention
versus -X- _ O
each -X- _ B-Comparison
monotherapy -X- _ I-Comparison
plus -X- _ I-Comparison
placebo. -X- _ I-Comparison
METHODS -X- _ O
AND -X- _ O
FINDINGS -X- _ O
: -X- _ O
We -X- _ O
conducted -X- _ O
a -X- _ O
randomized -X- _ O
placebo- -X- _ O
controlled -X- _ O
trial -X- _ O
with -X- _ O
145 -X- _ O
general -X- _ O
practitioners -X- _ O
throughout -X- _ O
France -X- _ O
during -X- _ O
the -X- _ O
2008–2009 -X- _ O
seasonal -X- _ B-Patient
influenza -X- _ I-Patient
epidemic. -X- _ I-Patient
Patients -X- _ O
, -X- _ O
general -X- _ O
practitioners -X- _ O
, -X- _ O
and -X- _ O
outcome -X- _ O
assessors -X- _ O
were -X- _ O
all -X- _ O
blinded -X- _ O
to -X- _ O
treatment -X- _ O
assignment. -X- _ O
Adult -X- _ O
outpatients -X- _ O
presenting -X- _ O
influenza-like -X- _ O
illness -X- _ O
for -X- _ O
less -X- _ O
than -X- _ O
36 -X- _ O
hours -X- _ O
and -X- _ O
a -X- _ O
positive -X- _ O
influenza -X- _ O
A -X- _ O
rapid -X- _ O
test -X- _ O
diagnosis -X- _ O
were -X- _ O
randomized -X- _ O
to -X- _ O
oseltamivir -X- _ B-Intervention
75 -X- _ I-Intervention
mg -X- _ I-Intervention
orally -X- _ I-Intervention
twice -X- _ I-Intervention
daily -X- _ I-Intervention
plus -X- _ I-Intervention
zanamivir -X- _ I-Intervention
10 -X- _ I-Intervention
mg -X- _ I-Intervention
by -X- _ I-Intervention
inhalation -X- _ I-Intervention
twice -X- _ I-Intervention
daily -X- _ I-Intervention
( -X- _ I-Intervention
OZ -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
oseltamivir -X- _ B-Comparison
plus -X- _ I-Comparison
inhaled -X- _ I-Comparison
placebo -X- _ I-Comparison
( -X- _ I-Comparison
O -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ I-Comparison
or -X- _ I-Comparison
zanamivir -X- _ I-Comparison
plus -X- _ I-Comparison
oral -X- _ I-Comparison
placebo -X- _ I-Comparison
( -X- _ I-Comparison
Z -X- _ I-Comparison
) -X- _ I-Comparison
. -X- _ O
Treatment -X- _ O
efficacy -X- _ O
was -X- _ O
assessed -X- _ O
virologically -X- _ O
according -X- _ O
to -X- _ O
the -X- _ O
proportion -X- _ O
of -X- _ O
patients -X- _ O
with -X- _ O
nasal -X- _ O
influenza -X- _ O
reverse -X- _ O
transcription -X- _ O
( -X- _ O
RT -X- _ O
) -X- _ O
-PCR -X- _ O
below -X- _ O
200 -X- _ O
copies -X- _ O
genome -X- _ O
equivalent -X- _ O
( -X- _ O
cgeq -X- _ O
) -X- _ O
/ -X- _ O
μl -X- _ O
at -X- _ O
day -X- _ O
2 -X- _ O
( -X- _ O
primary -X- _ O
outcome -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
clinically -X- _ O
to -X- _ O
the -X- _ O
time -X- _ O
to -X- _ O
alleviation -X- _ O
of -X- _ O
symptoms -X- _ O
until -X- _ O
day -X- _ O
14. -X- _ O
Overall -X- _ O
541 -X- _ B-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
900 -X- _ I-Outcome
planned -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
included -X- _ I-Outcome
( -X- _ I-Outcome
OZ -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
192 -X- _ I-Outcome
; -X- _ I-Outcome
O -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
176 -X- _ I-Outcome
; -X- _ I-Outcome
Z -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
173 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
49 -X- _ I-Outcome
% -X- _ I-Outcome
male -X- _ I-Outcome
, -X- _ I-Outcome
mean -X- _ I-Outcome
age -X- _ I-Outcome
39 -X- _ I-Outcome
years. -X- _ I-Outcome
In -X- _ I-Outcome
the -X- _ I-Outcome
intention-to-treat -X- _ I-Outcome
analysis -X- _ I-Outcome
conducted -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
447 -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
RT-PCR-confirmed -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
, -X- _ I-Outcome
46 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
59 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
34 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
OZ -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
157 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
O -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
141 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
Z -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
149 -X- _ I-Outcome
) -X- _ I-Outcome
arms -X- _ I-Outcome
had -X- _ I-Outcome
RT-PCR -X- _ I-Outcome
< -X- _ I-Outcome
200 -X- _ I-Outcome
cgeq -X- _ I-Outcome
/ -X- _ I-Outcome
μl -X- _ I-Outcome
( -X- _ I-Outcome
−13.0 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
[ -X- _ I-Outcome
CI -X- _ I-Outcome
] -X- _ I-Outcome
−23.1 -X- _ I-Outcome
to -X- _ I-Outcome
−2.9 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.025 -X- _ I-Outcome
; -X- _ I-Outcome
+12.3 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
2.39–22.2 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.028 -X- _ I-Outcome
for -X- _ I-Outcome
OZ -X- _ I-Outcome
/ -X- _ I-Outcome
O -X- _ I-Outcome
and -X- _ I-Outcome
OZ -X- _ I-Outcome
/ -X- _ I-Outcome
Z -X- _ I-Outcome
comparisons -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Mean -X- _ I-Outcome
day -X- _ I-Outcome
0 -X- _ I-Outcome
to -X- _ I-Outcome
day -X- _ I-Outcome
2 -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
decrease -X- _ I-Outcome
was -X- _ I-Outcome
2.14 -X- _ I-Outcome
, -X- _ I-Outcome
2.49 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
1.68 -X- _ I-Outcome
log -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
) -X- _ I-Outcome
cgeq -X- _ I-Outcome
/ -X- _ I-Outcome
μl -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.060 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.016 -X- _ I-Outcome
for -X- _ I-Outcome
OZ -X- _ I-Outcome
/ -X- _ I-Outcome
O -X- _ I-Outcome
and -X- _ I-Outcome
OZ -X- _ I-Outcome
/ -X- _ I-Outcome
Z -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Median -X- _ I-Outcome
time -X- _ I-Outcome
to -X- _ I-Outcome
alleviation -X- _ I-Outcome
of -X- _ I-Outcome
symptoms -X- _ I-Outcome
was -X- _ I-Outcome
4.0 -X- _ I-Outcome
, -X- _ I-Outcome
3.0 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
4.0 -X- _ I-Outcome
days -X- _ I-Outcome
( -X- _ I-Outcome
+1.0 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
0.0–4.0 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.018 -X- _ I-Outcome
; -X- _ I-Outcome
+0.0 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
−3.0 -X- _ I-Outcome
to -X- _ I-Outcome
3.0 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.960 -X- _ I-Outcome
for -X- _ I-Outcome
OZ -X- _ I-Outcome
/ -X- _ I-Outcome
O -X- _ I-Outcome
and -X- _ I-Outcome
OZ -X- _ I-Outcome
/ -X- _ I-Outcome
Z -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Four -X- _ I-Outcome
severe -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
were -X- _ I-Outcome
observed. -X- _ I-Outcome
Nausea -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
vomiting -X- _ I-Outcome
tended -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
more -X- _ I-Outcome
frequent -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
combination -X- _ I-Outcome
arm -X- _ I-Outcome
( -X- _ I-Outcome
OZ -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
13 -X- _ I-Outcome
; -X- _ I-Outcome
O -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
4 -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
Z -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
5 -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
In -X- _ O
adults -X- _ B-Patient
with -X- _ I-Patient
seasonal -X- _ I-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
mainly -X- _ I-Patient
H3N2 -X- _ I-Patient
virus -X- _ I-Patient
infection -X- _ I-Patient
, -X- _ O
the -X- _ O
oseltamivir-zanamivir -X- _ B-Outcome
combination -X- _ I-Outcome
appeared -X- _ I-Outcome
less -X- _ I-Outcome
effective -X- _ I-Outcome
than -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
monotherapy -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
not -X- _ I-Outcome
significantly -X- _ I-Outcome
more -X- _ I-Outcome
effective -X- _ I-Outcome
than -X- _ I-Outcome
zanamivir -X- _ I-Outcome
monotherapy. -X- _ I-Outcome
Despite -X- _ O
the -X- _ O
theoretical -X- _ O
potential -X- _ O
for -X- _ O
the -X- _ O
reduction -X- _ O
of -X- _ O
the -X- _ O
emergence -X- _ O
of -X- _ O
antiviral -X- _ O
resistance -X- _ O
, -X- _ O
the -X- _ O
lower -X- _ O
effectiveness -X- _ O
of -X- _ O
this -X- _ O
combination -X- _ O
calls -X- _ O
for -X- _ O
caution -X- _ O
in -X- _ O
its -X- _ O
use -X- _ O
in -X- _ O
clinical -X- _ O
practice. -X- _ O
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
www.ClinicalTrials.gov -X- _ O
NCT00799760 -X- _ O
Please -X- _ O
see -X- _ O
later -X- _ O
in -X- _ O
the -X- _ O
article -X- _ O
for -X- _ O
the -X- _ O
Editors -X- _ O
' -X- _ O
Summary -X- _ O

